Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Ups & SMEs

Set Alert for Start-Ups & SMEs

Finance Watch: Mega-Round Mania As RNA Therapeutics, Gene Editing Attract VC Cash

Private Company Edition: Two companies raised multiple hundreds of millions of dollars each helping to keep the number of $100m-plus venture capital mega-rounds on the rise in May. Also, Ascend raised $132.5m to make gene and cell therapies, and Nido emerged with $109m for neurological diseases.

Financing Innovation

ReNAgade Emerges With $300m To Pursue Extra-Hepatic Delivery Of RNA Medicines

ReNAgade Therapeutics came out of stealth mode with $300m to fund its proprietary technology for delivery of RNA medicines – including coding, editing and gene insertion modalities – beyond the liver.

Financing Innovation

X4 Pharma’s Success After Cutbacks Will Comfort Hard-Hit Biotechs

X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.

Commercial Companies

ASGCT Late Breakers: Pfizer’s Duchenne Results Underwhelm As Next-Gen Approaches Emerge

The congress’s late breakers highlight progress across cell and gene platforms and diseases, and Duchenne is in the spotlight as Sarepta’s SRP-9001 could soon gain accelerated approval.

Clinical Trials Companies

Investors Impressed With Dualyx Tregs Plans

The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001, which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."

Financing Immune Disorders

Amylyx’s ALS Treatment Relyvrio Beats Expectations Again

The rare disease drug launch continues to outperform expectations, though questions remain about demand and how long patients will remain on the treatment.

Neurology Commercial

Finance Watch: Mega-Rounds Make A Comeback, But Will VC Funding Totals Rise Too?

Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.

Finance Watch Business Strategies

Hasten, Orbital Raise 2023’s Biggest Venture Capital Rounds Days Apart

Hasten brought in $315m, and Orbital garnered $270m, but while multiple venture firms have raised large new funds, Q1 saw the lowest amount of biopharma VC fundraising in a single quarter since 2019.

Financing Business Strategies

Helping Universities Avoid The Pitfalls Of Biotech Spin-offs

Universities and venture capital firms have produced guidance that they hope will accelerate and support the founding of a new generation of start-ups.

Business Strategies StartUps and SMEs

Forbion Will Use New Fund To Rescue Struggling Biotechs

The Netherlands and Germany-based VC firm wants to help out public and private companies who have undervalued late-stage assets and are struggling to raise new funds.

Financing Commercial

ADC Deal Train Rolls On As BMS Taps Into Tubulis

The Munich-based firm has landed a big pharma partner in Bristol Myers Squibb, claiming the deal validates the potential of its approach in developing next-generation antibody-drug conjugates.

Deals StartUps and SMEs

Finance Watch: Venture Capital Funders Raise Billions For Biotech Investments

Private Company Edition: Forbion closed two funds totaling €1.35bn ($1.5bn) and Glide Healthcare raised €600m ($657.5m) for its latest fund, joining recent venture capital raises by Lux Capital and Wellington Management, but in the first quarter biopharma VC company financings fell dramatically.

Financing Innovation
See All
UsernamePublicRestriction

Register